This trial will test the safety of tolvaptan, a drug used to treat ARPKD, in children.
1 Primary · 5 Secondary · Reporting Duration: 1 month, 6 months, 12 months, and 18 months
Experimental Treatment
10 Total Participants · 2 Treatment Groups
Primary Treatment: Tolvaptan Tablets · No Placebo Group · Phase 3
Age 28 - 18 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: